KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) FCF Margin (2019 - 2025)

Royalty Pharma's FCF Margin history spans 7 years, with the latest figure at 15.03% for Q4 2025.

  • For Q4 2025, FCF Margin fell 2643.0% year-over-year to 15.03%; the TTM value through Dec 2025 reached 33.43%, up 2180.0%, while the annual FY2025 figure was 33.31%, 2168.0% up from the prior year.
  • FCF Margin for Q4 2025 was 15.03% at Royalty Pharma, down from 115.32% in the prior quarter.
  • Across five years, FCF Margin topped out at 129.62% in Q4 2023 and bottomed at 228.08% in Q3 2021.
  • The 5-year median for FCF Margin is 15.03% (2025), against an average of 13.78%.
  • The largest annual shift saw FCF Margin surged 24251bps in 2023 before it plummeted -19388bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 55.28% in 2021, then increased by 2bps to 56.51% in 2022, then soared by 129bps to 129.62% in 2023, then tumbled by -68bps to 41.46% in 2024, then crashed by -64bps to 15.03% in 2025.
  • Per Business Quant, the three most recent readings for RPRX's FCF Margin are 15.03% (Q4 2025), 115.32% (Q3 2025), and 0.19% (Q1 2025).